Mainz Biomed B.V. (MYNZ) Stock Analysis

Mainz Biomed B.V. (MYNZ) Healthcare & Pipeline Overview

Mainz Biomed B.V. is a German molecular genetics company focused on developing advanced in-vitro diagnostic tools and assays for cancer detection and pathogen identification. Its portfolio includes ColoAlert for colorectal cancer screening and PancAlert in development for pancreatic cancer, positioning it in the evolving landscape of non-invasive diagnostics within human genetics.

What Is the Investment Thesis for MYNZ?

Mainz Biomed B.V. operates within the growing molecular diagnostics market, focusing on early cancer detection, a segment driven by increasing demand for non-invasive screening methods. The company's lead product, ColoAlert, for colorectal cancer screening, positions it to capitalize on this trend. The ongoing development of PancAlert for pancreatic cancer represents a significant future growth catalyst, addressing a critical unmet medical need for early detection in a highly aggressive disease. Financially, the company reported a robust Gross Margin of 100.0%, indicating strong control over its cost of goods sold, despite a negative Profit Margin of -2937.8%, which is common for development-stage biotech firms. With a Market Cap of $14.7M and a Beta of 0.32, the company exhibits lower volatility relative to the broader market. Key value drivers include successful clinical development and regulatory approvals for PancAlert, and expanded market penetration for ColoAlert. However, investors may want to evaluate the inherent risks associated with regulatory hurdles, intense competition from established players in the diagnostics market, and the capital-intensive nature of product development.

Based on FMP financials and quantitative analysis

MYNZ Key Highlights

Market Capitalization: $14.7M, reflecting its early-stage or specialized market position.

• Gross Margin: 100.0%, indicating efficient cost management relative to its revenue generation.
• Profit Margin: -2937.8%, typical for a company in the research and development phase with significant investment in pipeline products.
• Employee Count: 19 employees, suggesting a lean operational structure focused on specialized expertise.
• Beta: 0.32, indicating lower volatility compared to the overall market.

Who Are MYNZ's Competitors?

MYNZ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are MYNZ's Key Strengths?

Specialized expertise in molecular genetics for diagnostics.

• Proprietary product ColoAlert addresses a significant market need for colorectal cancer screening.
• Strong Gross Margin of 100.0% indicates efficient cost of goods sold.
• Pipeline product PancAlert targets an unmet need in pancreatic cancer screening.

What Are MYNZ's Weaknesses?

Highly negative Profit Margin of -2937.8% indicates substantial operating losses.

• Relatively small market capitalization of $14.7M.
• Small employee base of 19, potentially limiting scalability and breadth of operations.
• Reliance on successful development and commercialization of pipeline products.

What Could Drive MYNZ Stock Higher?

MYNZ catalyst: Announcement of significant progress or successful completion of clinical trials for PancAlert, advancing its path towards regulatory submission.

• Receipt of new regulatory approvals for ColoAlert in additional key international markets, expanding its commercial reach.
• Continued expansion of market penetration and adoption rates for ColoAlert, driven by increasing demand for non-invasive colorectal cancer screening.
• Formation of strategic partnerships or collaborations to accelerate the development or commercialization of pipeline products.

What Are the Key Risks for MYNZ?

Financial-distress signal — its Altman Z-Score of -8.40 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 7 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory hurdles and delays in obtaining necessary approvals for PancAlert or other pipeline products, impacting market entry timelines.
• Intense competition from established diagnostic companies with greater resources and market presence, potentially limiting market share for Mainz Biomed's products.
• Clinical trial risks, including the possibility of unexpected results, delays, or failure to meet endpoints for PancAlert, which could impede its commercialization.
• Financial risks associated with a significant negative Profit Margin of -2937.8%, indicating ongoing operational losses and potential need for future capital raises.
• Challenges in achieving broad market acceptance and favorable reimbursement policies for new diagnostic tests, which can hinder commercial success.

What Are the Growth Opportunities for MYNZ?

• ColoAlert Market Adoption and Expansion: The increasing global emphasis on early cancer detection and the adoption of non-invasive screening methods present a significant growth opportunity for ColoAlert. As a screening test for colorectal cancer, ColoAlert is positioned to benefit from public health initiatives and patient preference for less invasive diagnostic options. Expanding its market penetration within existing regions and securing regulatory approvals for new geographic markets could substantially increase its user base and revenue streams. The market for colorectal cancer screening is substantial, driven by aging populations and rising incidence rates, offering a robust environment for ColoAlert's continued growth.
• PancAlert Development and Commercialization: The development and eventual commercialization of PancAlert for pancreatic cancer screening represent a major growth catalyst. Pancreatic cancer is often diagnosed at advanced stages due to a lack of effective early screening tools, leading to poor prognoses. PancAlert aims to address this critical unmet medical need, potentially opening access to a high-value market segment. Successful clinical trials, regulatory approvals, and subsequent market launch could significantly transform Mainz Biomed's revenue profile and establish it as a key player in early pancreatic cancer diagnostics.
• GenoStrip Application and Market Diversification: GenoStrip, Mainz Biomed's molecular genetic solution for identifying pathogens, offers diversification beyond cancer diagnostics. This product has potential for expanded applications in various environments, including clinical settings for infectious disease diagnosis, food safety, environmental monitoring, and agricultural testing. Broadening the scope of GenoStrip's utility and targeting new market segments could unlock additional revenue streams and reduce the company's reliance on its cancer diagnostic pipeline, leveraging its core molecular genetics expertise across different industries.
• Leveraging Molecular Genetics Platform for New Diagnostics: Mainz Biomed's core expertise in molecular genetics provides a robust platform for developing new diagnostic tools beyond its current cancer and pathogen detection focus. The company could explore diagnostic solutions for other life-threatening diseases, rare genetic conditions, or companion diagnostics for targeted therapies. This strategic expansion into new therapeutic or diagnostic areas, driven by its foundational technology, could open up entirely new market opportunities and diversify its product pipeline, fostering long-term growth and innovation.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies, diagnostic laboratories, or healthcare providers could accelerate market access and product development. Collaborations could provide Mainz Biomed with additional funding, broader distribution networks, and enhanced research capabilities, particularly for complex clinical trials or market launches in new territories. Such alliances could significantly de-risk product commercialization and expand the reach of ColoAlert, PancAlert, and GenoStrip, leveraging external resources to drive growth.

What Are MYNZ's Competitive Advantages?

• Specialized Molecular Genetics Expertise: Deep knowledge and proprietary technology in molecular genetics, forming the foundation for its diagnostic platforms.
• Proprietary Diagnostic Products: Development and ownership of unique diagnostic tests like ColoAlert and the pipeline candidate PancAlert, addressing specific medical needs.
• Focus on Early Cancer Detection: Strategic positioning in the high-growth and high-impact segment of early cancer screening, particularly for challenging cancers.
• Regulatory Approvals: Attainment of necessary regulatory approvals for its products, creating barriers to entry for competitors.

What Does MYNZ Do?

Mainz Biomed B.V., established in 2008 and headquartered in Mainz, Germany, is a specialized molecular genetics company dedicated to advancing cancer diagnostics. The firm engineers sophisticated in-vitro diagnostic (IVD) tools and assays, primarily for research applications within human genetics. Its core mission revolves around developing solutions for early detection of life-threatening diseases. A cornerstone of its product portfolio is ColoAlert, a non-invasive screening test specifically designed for the detection of colorectal cancer. This product addresses a significant medical need by offering a convenient and effective method for early diagnosis, which is crucial for improving patient outcomes. Beyond existing offerings, Mainz Biomed is actively engaged in the development of PancAlert, a promising product candidate aimed at pancreatic cancer screening. Pancreatic cancer is known for its aggressive nature and late-stage diagnosis, making early screening tools like PancAlert potentially transformative. In addition to its cancer-focused pipeline, the company diversifies its molecular genetic expertise through GenoStrip, a solution engineered for identifying pathogens across various environments. This broader application demonstrates the versatility of Mainz Biomed's technological platform. With a focused team of 19 employees, the company maintains its commitment to innovation in molecular diagnostics, aiming to provide impactful solutions in clinical applications and research.

What Products and Services Does MYNZ Offer?

• Develops molecular genetic diagnostic solutions for life-threatening diseases.
• Specializes in the field of cancer diagnostics.
• Offers ColoAlert, a non-invasive screening test for colorectal cancer.
• Is developing PancAlert, a product candidate for pancreatic cancer screening.
• Provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments.
• Engineers in-vitro diagnostic (IVD) tools.
• Creates assays designed exclusively for research, primarily for clinical applications.
• Focuses on human genetics applications for its diagnostic products.

How Does MYNZ Make Money?

• Generates revenue from the sales of its in-vitro diagnostic tests, primarily ColoAlert for colorectal cancer screening.
• Derives income from the provision of molecular genetic assays and IVD tools for research purposes in clinical human genetics.
• Anticipates future revenue streams from the commercialization of pipeline products such as PancAlert, upon successful development and regulatory approval.
• Aims to expand revenue through the broader application and market penetration of its GenoStrip pathogen identification solution.

What Industry Does MYNZ Operate In?

Mainz Biomed B.V. is positioned within the dynamic Medical - Diagnostics & Research industry, specifically leveraging molecular genetics for cancer diagnostics. The broader healthcare sector is experiencing a significant shift towards personalized medicine and early disease detection, with a growing emphasis on non-invasive screening methods. Mainz Biomed's ColoAlert aligns directly with this trend, addressing the substantial market for colorectal cancer screening. The development of PancAlert further places the company in the high-need segment of pancreatic cancer diagnostics, where early detection remains a critical challenge. The competitive landscape includes established diagnostic companies and emerging biotech firms, all vying for market share with innovative screening technologies. Mainz Biomed differentiates itself through its specialized molecular genetic platform and focused pipeline, aiming to capture value in specific, high-impact diagnostic areas within this evolving market.

Who Are MYNZ's Key Customers?

• Clinical laboratories and diagnostic centers seeking advanced molecular genetic tests.
• Healthcare providers, including hospitals and specialist clinics, utilizing cancer screening tools.
• Research institutions and academic centers requiring specialized assays for human genetics studies.
• Environmental and public health agencies utilizing pathogen identification solutions.

Over the past six months, Mainz Biomed B.V. insiders filed 4 SEC Form 4 transactions — 0 sales and 4 purchases. On net that is roughly 2.3M shares acquired (about $0) — insiders putting money in tends to read as conviction.

Wall Street analysts project Mainz Biomed B.V. revenue of about $2.0M for fiscal 2026, with EPS near $-0.49.

Mainz Biomed B.V. has missed Wall Street's EPS estimate in 6 of its last 7 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 2836.0% below estimates on average.

Mainz Biomed B.V.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.40 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Its free cash flow yield is -29.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.11 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -46.9%, the inverse of the P/E and a quick read on earnings relative to price.

Mainz Biomed B.V. (MYNZ) Valuation Context

Valued at $14.7M, MYNZ is classified as a micro-cap stock.

MYNZ Revenue & Earnings Trend

In Jun 2026, MYNZ generated $0 in top-line revenue, marking a sequential decrease of 100.0%. The company recorded a net loss of $11.0M, with diluted EPS of $-0.62. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, MYNZ averaged $-3.89 in diluted EPS.

Company Profile

Mainz Biomed B.V. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Mainz, DE. The company is led by CEO Guido Baechler. MYNZ has traded publicly since 2021.

MYNZ Financials

MYNZ Latest News

MYNZ Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources